trial · primary record
Cefazolin 2 g Infusion
Breast Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1600 |
| Primary completion | 2029-01 |
| Primary endpoint | Proportion of patients with any surgical site infection (SSI) |
| Registry ID | NCT07898943 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:38.539Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07898943
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.